Intersect ENT Inc (XENT) Receives Consensus Recommendation of “Buy” from Analysts
Intersect ENT Inc (NASDAQ:XENT) has earned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $33.43.
Several equities analysts have issued reports on XENT shares. Northland Securities reiterated a “hold” rating and issued a $25.00 price objective on shares of Intersect ENT in a research report on Friday, November 3rd. BidaskClub downgraded Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. JPMorgan Chase & Co. upgraded Intersect ENT from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Zacks Investment Research downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price objective on shares of Intersect ENT in a research report on Monday, December 11th.
Shares of Intersect ENT (NASDAQ:XENT) opened at $34.35 on Monday. Intersect ENT has a one year low of $11.75 and a one year high of $35.34. The company has a market capitalization of $1,011.81, a price-to-earnings ratio of -54.52 and a beta of 0.67.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. During the same quarter in the previous year, the company posted ($0.22) EPS. The business’s revenue for the quarter was up 20.8% compared to the same quarter last year. equities research analysts predict that Intersect ENT will post -0.63 earnings per share for the current year.
In other news, General Counsel David Aaron Lehman sold 36,000 shares of the business’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $32.75, for a total transaction of $1,179,000.00. Following the completion of the sale, the general counsel now owns 45,000 shares in the company, valued at $1,473,750. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Jeryl L. Hilleman sold 12,835 shares of the business’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $33.81, for a total value of $433,951.35. Following the sale, the chief financial officer now owns 25,767 shares of the company’s stock, valued at approximately $871,182.27. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 106,886 shares of company stock valued at $3,320,094. 13.70% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in XENT. Great West Life Assurance Co. Can bought a new stake in shares of Intersect ENT during the third quarter worth $116,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Intersect ENT during the third quarter worth $117,000. Legal & General Group Plc increased its holdings in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 255 shares during the last quarter. Moors & Cabot Inc. bought a new stake in Intersect ENT in the second quarter valued at about $205,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Intersect ENT in the third quarter valued at about $228,000. Institutional investors own 86.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Intersect ENT Inc (XENT) Receives Consensus Recommendation of “Buy” from Analysts” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/intersect-ent-inc-xent-receives-consensus-recommendation-of-buy-from-analysts/1807677.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.